Abstract: A method of treating cancer in a subject includes contacting an enriched population of T-cells obtained from cancer or tumor draining lymph nodes ex-vivo with: an anti-CD3 antibody, an anti-CD28 antibody, and/or functional fragments thereof, and optionally a VEGF inhibitor and/or an IL-2 receptor agonist, at amounts effective to activate and expand the T-cells and administering the activated and expanded T-cells to the subject.
Type:
Grant
Filed:
April 16, 2018
Date of Patent:
July 27, 2021
Assignee:
CASE WESTERN RESERVE UNIVERSITY
Inventors:
Julian Kim, Kevin Choong, Hallie Graor, Mei Zhang, John Ammori, Anthony Visioni
Abstract: Methods of mitigating the risk of rejection of an allograft or xenograft in an incompatible recipient by neutralizing one or more populations of circulating antibody cross-reactive with a carbohydrate antigen expressed by the allograft or xenograft. The method includes administering to the recipient by intravenous infusion a concentration of a synthetic antigen lipid construct sufficient to neutralize the one or more populations of circulating antibody in the recipient.
Type:
Grant
Filed:
November 9, 2018
Date of Patent:
July 6, 2021
Assignee:
KODE BIOTECH LIMITED
Inventors:
Stephen Micheal Henry, Caroline Ann Oliver
Abstract: The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. Such TILs find use in therapeutic treatment regimens.
Type:
Grant
Filed:
December 18, 2020
Date of Patent:
July 6, 2021
Assignee:
Iovance Biotherapeutics, Inc.
Inventors:
Seth Wardell, James Bender, Michael T. Lotze
Abstract: The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. Such TILs find use in therapeutic treatment regimens.
Type:
Grant
Filed:
December 18, 2020
Date of Patent:
July 6, 2021
Assignee:
Iovance Biotherapeutics, Inc.
Inventors:
Seth Wardell, James Bender, Michael T. Lotze
Abstract: The present invention provides improved and/or shortened methods for expanding TLs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TLs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. Such TLs find use in therapeutic treatment regimens.
Type:
Grant
Filed:
January 12, 2021
Date of Patent:
June 22, 2021
Assignee:
Iovance Biotherapeutics, Inc.
Inventors:
Seth Wardell, James Bender, Michael T. Lotze
Abstract: Methods and compositions are provided for combined transplantation of a solid organ and hematopoietic cells to a recipient, where tolerance to the graft is established through development of a persistent mixed chimerism. An individual with persistent mixed chimerism, usually for a period of at least six months, is able to withdraw from the use of immunosuppressive drugs after a period of time sufficient to establish tolerance.
Type:
Grant
Filed:
May 1, 2018
Date of Patent:
June 22, 2021
Assignee:
The Board of Trustees of the Leland Stanford Junior University
Abstract: A method of treating an injury to hyaline cartilage in a subject in need thereof. The method comprises administering to the subject a therapeutically effective amount of amelogenin.
Type:
Grant
Filed:
February 20, 2018
Date of Patent:
June 15, 2021
Assignees:
YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD., HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
Inventors:
Dan Deutsch, Amir Haze, Anat Blumenfeld
Abstract: The invention concerns a method of generating an immune response in a subject, comprising administering to the subject an antigenic molecule, a photosensitizing agent, a checkpoint inhibitor, and irradiating said subject with light of a wavelength effective to activate the photosensitizing agent to generate an immune response. Preferably the method is a method of vaccination. The invention also provides related methods, compositions, cells, uses, products and kits.
Abstract: Methods and compositions are provided for combined transplantation of a solid organ and hematopoietic cells to a recipient, where tolerance to the graft is established through development of a persistent mixed chimerism. An individual with persistent mixed chimerism, usually for a period of at least six months, is able to withdraw from the use of immunosuppressive drugs after a period of time sufficient to establish tolerance.
Type:
Grant
Filed:
November 20, 2018
Date of Patent:
June 1, 2021
Assignee:
The Board of Trustees of the Leland Stanford Junior University
Abstract: The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. Such TILs find use in therapeutic treatment regimens.
Type:
Grant
Filed:
January 12, 2021
Date of Patent:
May 25, 2021
Assignee:
Iovance Biotherapeutics, Inc.
Inventors:
Seth Wardell, James Bender, Michael T. Lotze
Abstract: Methods and compositions are provided for combined transplantation of a solid organ and hematopoietic cells to a recipient, where tolerance to the graft is established through development of a persistent mixed chimerism. An individual with persistent mixed chimerism, usually for a period of at least six months, is able to withdraw from the use of immunosuppressive drugs after a period of time sufficient to establish tolerance.
Type:
Grant
Filed:
November 26, 2018
Date of Patent:
May 18, 2021
Assignee:
The Board of Trustees of the Leland Stanford Junior University
Abstract: The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. Such TILs find use in therapeutic treatment regimens.
Type:
Grant
Filed:
December 18, 2020
Date of Patent:
May 18, 2021
Assignee:
Iovance Biotherapeutics, Inc.
Inventors:
Seth Wardell, James Bender, Michael T. Lotze
Abstract: The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. Such TILs find use in therapeutic treatment regimens.
Type:
Grant
Filed:
December 18, 2020
Date of Patent:
May 18, 2021
Assignee:
lovance Biotherapeutics, Inc.
Inventors:
Seth Wardell, James Bender, Michael T. Lotze
Abstract: Conventional cancer immunotherapy falls short at efficiently expanding T cells that specifically target cancerous cells in numbers sufficient to significantly reduce the tumor size or cancerous cell number in vivo. To overcome this limitation, provided herein are nanoparticles coated with MHC class I and/or class II molecules presenting tumor-specific antigens and co-stimulatory molecules and their use to expand antigen-specific anti-tumorigenic T cells to levels not achieved in current immunotherapeutic techniques. These antigen-specific anti-tumorigenic T cells include cytotoxic T cells, effector T cells, memory T cells, and helper T cells that are necessary to initiate and maintain a substantial immune response against metastatic or non-metastatic cancerous, pre-cancerous, or neoplastic cells in vivo. The present invention describes a systemic approach to targeting cancerous or pre-cancerous cells that are circulating cells, as in lymphomas, migratory metastatic cells, and solid tumors.
Abstract: The present disclosure provides isolated monoclonal antibodies that specifically bind to LAG-3 with high affinity, particularly human monoclonal antibodies. Preferably, the antibodies bind human LAG-3. In certain embodiments, the antibodies bind both human and monkey LAG-3 but do not bind mouse LAG-3. The invention provides anti-LAG-3 antibodies that can inhibit the binding of LAG-3 to WIC Class II molecules and that can stimulate antigen-specific T cell responses. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. This disclosure also provides methods for detecting LAG-3, as well as methods for treating stimulating immune responses using an anti-LAG-3 antibody of the invention.
Type:
Grant
Filed:
August 21, 2020
Date of Patent:
May 11, 2021
Assignee:
E.R. Squibb & Sons, L.L.C.
Inventors:
Kent B. Thudium, Mark J. Selby, Kyra D. Zens, Mark Yamanaka, Alan J. Korman, Heidi N. LeBlanc
Abstract: The present disclosure provides isolated monoclonal antibodies that specifically bind to LAG-3 with high affinity, particularly human monoclonal antibodies. Preferably, the antibodies bind human LAG-3. In certain embodiments, the antibodies bind both human and monkey LAG-3 but do not bind mouse LAG-3. The invention provides anti-LAG-3 antibodies that can inhibit the binding of LAG-3 to MHC Class II molecules and that can stimulate antigen-specific T cell responses. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. This disclosure also provides methods for detecting LAG-3, as well as methods for treating stimulating immune responses using an anti-LAG-3 antibody of the invention.
Type:
Grant
Filed:
August 21, 2020
Date of Patent:
April 27, 2021
Assignee:
E.R. Squibb & Sons, L.L.C.
Inventors:
Kent B. Thudium, Mark J. Selby, Kyra D. Zens, Mark Yamanaka, Alan J. Korman, Heidi N. Leblanc
Abstract: The present disclosure provides isolated monoclonal antibodies that specifically bind to LAG-3 with high affinity, particularly human monoclonal antibodies. Preferably, the antibodies bind human LAG-3. In certain embodiments, the antibodies bind both human and monkey LAG-3 but do not bind mouse LAG-3. The invention provides anti-LAG-3 antibodies that can inhibit the binding of LAG-3 to MHC Class II molecules and that can stimulate antigen-specific T cell responses. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. This disclosure also provides methods for detecting LAG-3, as well as methods for treating stimulating immune responses using an anti-LAG-3 antibody of the invention.
Type:
Grant
Filed:
May 22, 2019
Date of Patent:
April 27, 2021
Assignee:
E.R. Squibb & Sons, L.L.C.
Inventors:
Kent B. Thudium, Mark J. Selby, Kyra D. Zens, Mark Yamanaka, Alan J. Korman, Heidi N. Leblanc
Abstract: This disclosure describes the identification of pre-B Cell Receptor (pre-BCR) antagonists and the use of pre-BCR antagonists as a targeted therapy. The compositions and methods generally involve a composition that includes a pre-B cell receptor (pre-BCR) antagonist and is engineered for expression as a T cell chimeric receptor. In some embodiments, the pre-BCR antagonists can include an anti-pre-BCR antibody.
Type:
Grant
Filed:
February 5, 2016
Date of Patent:
April 27, 2021
Assignees:
UNM Rainforest Innovations
Inventors:
Bridget S. Wilson, Stuart S. Winter, Michael Frank Erasmus, Michael Horowitz
Abstract: Described herein are human transgenic beta cells expressing fugetactic levels of CXCL12 to a subject in need thereof. Also described herein are beta cells comprising a transgene comprising a nucleic acid sequence encoding CXCL12.
Abstract: The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. Such TILs find use in therapeutic treatment regimens.
Type:
Grant
Filed:
April 14, 2020
Date of Patent:
March 23, 2021
Assignee:
Iovance Biotherapeutics, Inc.
Inventors:
Seth Wardell, James Bender, Michael T. Lotze